BeOne Medicines

#News for #Investors and #Media: BeOne Medicines announces third quarter 2026 financial results and business updates.

Read the full press release here: ir.beonemedicines.com/news/beone-med…

#News for #Investors and #Media: The U.S. FDA has granted priority review for our foundational BTK inhibitor in combination with rituximab for first-line mantle cell lymphoma (#MCL) patients. If approved, this BTKi-based regimen would be the first and only chemotherapy-free option for MCL patients in the United States. Full results from the Phase 3 MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting.

Read the full announcement: ir.beonemedicines.com/news/us-fda-gr…

#Oncology #BeOneInnovator

Adiós, Madrid. #ESMO2026 brought bold thinking, new science and a global oncology community together. We leave determined to keep changing the game through oncology innovation and pushing what’s possible for people with cancer.

Learn more: bit.ly/47t2X4o

#TeamBeOne

#TeamBeOne shares what’s emerging at #ESMO26, their take on the science, and what it could mean for the field – and for patients.

Discover how we’re changing the game in solid tumor oncology: bit.ly/47t2X4o

#TeamBeOne #FromFloorToFeed

#News for #Investors and #Media: At #ESMO2026, we’re presenting new data from across our advancing solid tumor pipeline, spanning four priority programs with distinct molecular approaches, highlighting the innovation and scale of our solid tumor portfolio.

Explore the data here: ir.beonemedicines.com/news/beone-pre…

#BeOneInnovator